Immune complex vasculitis after COVID-19 vaccination with BNT162b2

A 76-year-old Caucasian male with a history of compensated alcoholic liver cirrhosis, NYHA II heart failure, gastrectomy after gastroesophageal junction cancer and prostatectomy after prostate cancer and indwelling suprapubic catheter noticed lesions on hands and feet ~12 days after his second mRNA-based vaccination for COVID-19 with BNT162b2.

Physical examination in outpatient clinic revealed symmetric distal limb swelling, and a purpuric rash with palpable maculae on extensor and flexor parts of both hands, legs and thighs reaching up to the lower abdomen. The patient denied symptoms of fever, dyspnea, arthralgia or anuria, but he reported of melaena and diarrhea the day before. The patient had no history of allergic predispositions or systemic autoimmune diseases. He denied having started any new medication recently or any changing in alimentary habits. After his first vaccination with BNT162b2 6 weeks earlier, he had experienced significant vaccine related myalgia, fever (39.5 °C), hoarseness and fatigue, yet no skin related adverse events had occurred. 

Laboratory findings revealed elevated blood sedimentations rate, interleukin-6 levels and C-reactive protein levels. In addition, signs of discrete hemolysis and elevated ammonium levels could be detected. Stool tests on occult blood was positive and stool calprotectin levels were moderately elevated. Virological tests on human herpes viruses and further human pathogenic viruses showed no new reactivation or infection.

The patient was started on 40 mg oral prednisolone once daily. Skin lesions were resolved on the fifth day of steroid therapy.

READ MORE

REFERENCE

Mücke VT, Knop V, Mücke MM, Ochsendorf F, Zeuzem S. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report. BMC Infectious Diseases. 2021 Dec;21(1):1-6.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

Image
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead.  From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear.  The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2
Read more